Novo Nordisk and Gilead team up to test fatty liver disease treatment


By Reuters Staff

COPENHAGEN (Reuters) - Novo Nordisk and Gilead Sciences will join forces on a clinical trial combining drugs from the two pharmaceutical firms to treat a progressive fatty liver disease known as NASH.

The clinical trial will be a study combining Novo Nordisk's semaglutide drug and Gilead's cilofexor and firsocostat for treatment of patients with Nonalcoholic steatohepatitis (NASH), Novo Nordisk said on Friday.

"NASH is a complex disease that often affects people with diabetes and metabolic syndrome. Currently, patients living with NASH have limited treatment options," said Gilead's chief scientific officer John McHutchison in a statement.

In February, Gilead said a late-stage study of the experimental drug selonsertib aimed at treating NASH failed to meet its main goal.

Analysts have projected the market for NASH treatments to reach $20 billion to $35 billion as populations increasingly develop the disease fueled by obesity and diabetes.

Without treatment, patients with NASH can develop fibrosis, cirrhosis and cancer.

Novo is currently testing semaglutide, already approved to treat diabetes, as a once-daily treatment for NASH in phase 2. Gilead's Cilofexor and firsocostat have not been approved by any regulatory authorities.

Related Articles

IBD patients who switch from infliximab to biosimilar see mixed results

By Will Boggs MD NEW YORK (Reuters Health) - Patients with inflammatory bowel disease (IBD) can safely switch from infliximab to the biosimilar CT-P13, though they may face a higher risk of clinical Read More »

Yale study revives cellular activity in pig brains hours after death

By Steve Gorman (Reuters) - Yale University scientists have succeeded in restoring basic cellular activity in pigs' brains hours after their deaths in a finding that may one day lead to advances in Read More »

Penalizing US hospitals for readmissions doesn't benefit heart failure patients

By Marilynn Larkin NEW YORK (Reuters Health) - Implementation of the U.S. Hospital Readmissions Reduction Program (HRRP) in the past decade has not been associated with changes in hospital length of Read More »